{
  "id": 3969916,
  "title": "FDA green lights Priovant drug for rare skin disease",
  "url": "https://urgent.news/2026/08/28/fda-green-lights-priovant-drug-for-rare-skin-disease",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-28T13:12:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/fda-priovant-pfizer-lisraya-brepocitinib-approved/829021/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Lisraya’s clearance marks the first approval of a drug the Roivant subsidiary licensed from Pfizer and has since positioned against multiple rare inflammatory conditions.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "STAT News",
        "title": "STAT+: FDA approves Roivant therapy for rare autoimmune disease",
        "url": "https://urgent.news/2026/08/27/stat-fda-approves-roivant-therapy-for-rare-autoimmune-disease",
        "published": "2026-08-27T19:47:01.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}